Kyoichiro Tsuchiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kyoichiro Tsuchiya has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
Hiroyuki Uchinuma
13 shared publications- Nozomi Harai
Department of Endocrinology and Metabolism Toranomon Hospital Tokyo Japan
8 shared publications Hideyuki Okuma
Department of Diabetes and Endocrinology Graduate School of Interdisciplinary Research Faculty of Medicine University of Yamanashi Chuo Yamanashi Japan
7 shared publicationsYasutaka Miyachi
Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
7 shared publicationsKumiko Shiba
Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
6 shared publicationsMegumi Kushima
6 shared publications
Latest Publications
- 24 October 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Targeted long-read sequencing reveals allele-specific methylation profiles at the GNAS locus in pseudohypoparathyroidism with various etiologies
Patients with pseudohypoparathyroidism (PHP) show PTH resistance due to reduced Gsα expression. Loss-of-function variants in maternal Gsα-coding exons cause PHP type 1A (PHP1A), and methylation defects in GNAS-differentially methylated regions (DMRs) at the GNAS locus cause PHP type 1B (PHP1B). The GNAS-AS1:TSS-DMR (AS1-DMR), GNAS-AS2:TSS-DMR (AS2-DMR), GNAS-XL:Ex1-DMR (XL-DMR), and GNAS-A/B:TSS-DMR (A/B-DMR) are maternally methylated. The GNAS-NESP:TSS-DMR (NESP-DMR) is paternally methylated. STX16 functions as a long-range enhancer for NESP55 and XL. PHP1B cases commonly exhibit hypomethylated A/B-DMR and various methylation patterns in other GNAS-DMRs; however, the regulatory mechanisms for methylation patterns in GNAS-DMRs remain unclear. We evaluated allele-specific methylation levels for all CpGs within the GNAS locus together with structural abnormalities using targeted long-read sequencing (T-LRS) in a PHP1A case with a deletion affecting the 3′ side A/B-DMR to GNAS exon 1, 8 PHP1B cases (3 familial cases [maternal STX16 deletion, maternal GNAS duplication, and retrotransposon insertion on the maternal allele], a sporadic case with STX16 deletion, and 4 epimutation cases [2 typical and 2 atypical methylation patterns]), and an individual with paternal GNAS duplication showing normal phenotype. The PHP1A case showed normal methylation at the intact A/B-DMR, narrowing the critical region for the establishment and/or maintenance of the maternal methylation imprint in the A/B-DMR. The case with STX16 deletion and the case with maternal duplication causing elongation of the distance between STX16 and the AS2-DMR showed hypomethylated AS2-DMR, suggesting the incomplete enhancer effect of STX16 on the AS2-DMR. Furthermore, we detected the precise region of the AS2-DMR. The case with retrotransposon insertion (chr20:58 863 683) showed markedly hypomethylated A/B-DMR, plus mild hypomethylation of the AS1-DMR, AS2-DMR, and XL-DMR, undetected by conventional methylation analyses. Sporadic cases exhibited mosaic methylation abnormalities in all GNAS-DMRs, indicating that abnormal methylation occurred during early embryogenesis. Targeted-LRS is a powerful tool for clarifying methylation pattern regulation in GNAS-DMRs.
- 24 October 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Targeted long-read sequencing reveals allele-specific methylation profiles at the GNAS locus in pseudohypoparathyroidism with various etiologies
Patients with pseudohypoparathyroidism (PHP) show PTH resistance due to reduced Gsα expression. Loss-of-function variants in maternal Gsα-coding exons cause PHP type 1A (PHP1A), and methylation defects in GNAS-differentially methylated regions (DMRs) at the GNAS locus cause PHP type 1B (PHP1B). The GNAS-AS1:TSS-DMR (AS1-DMR), GNAS-AS2:TSS-DMR (AS2-DMR), GNAS-XL:Ex1-DMR (XL-DMR), and GNAS-A/B:TSS-DMR (A/B-DMR) are maternally methylated. The GNAS-NESP:TSS-DMR (NESP-DMR) is paternally methylated. STX16 functions as a long-range enhancer for NESP55 and XL. PHP1B cases commonly exhibit hypomethylated A/B-DMR and various methylation patterns in other GNAS-DMRs; however, the regulatory mechanisms for methylation patterns in GNAS-DMRs remain unclear. We evaluated allele-specific methylation levels for all CpGs within the GNAS locus together with structural abnormalities using targeted long-read sequencing (T-LRS) in a PHP1A case with a deletion affecting the 3′ side A/B-DMR to GNAS exon 1, 8 PHP1B cases (3 familial cases [maternal STX16 deletion, maternal GNAS duplication, and retrotransposon insertion on the maternal allele], a sporadic case with STX16 deletion, and 4 epimutation cases [2 typical and 2 atypical methylation patterns]), and an individual with paternal GNAS duplication showing normal phenotype. The PHP1A case showed normal methylation at the intact A/B-DMR, narrowing the critical region for the establishment and/or maintenance of the maternal methylation imprint in the A/B-DMR. The case with STX16 deletion and the case with maternal duplication causing elongation of the distance between STX16 and the AS2-DMR showed hypomethylated AS2-DMR, suggesting the incomplete enhancer effect of STX16 on the AS2-DMR. Furthermore, we detected the precise region of the AS2-DMR. The case with retrotransposon insertion (chr20:58 863 683) showed markedly hypomethylated A/B-DMR, plus mild hypomethylation of the AS1-DMR, AS2-DMR, and XL-DMR, undetected by conventional methylation analyses. Sporadic cases exhibited mosaic methylation abnormalities in all GNAS-DMRs, indicating that abnormal methylation occurred during early embryogenesis. Targeted-LRS is a powerful tool for clarifying methylation pattern regulation in GNAS-DMRs.
- Open Access
- 23 September 2026
- Published by Elsevier in SSRN Electronic Journal
Screen Time And Digital Device Use During Infant Feeding In Relation To Postpartum Depressive Symptoms: A Nationwide Cohort Analysis From The Japan Environment And Children’s Study
Background: Postpartum depression is common after delivery. With widespread smartphone use, concerns have arisen about its influence on maternal mental health. We examined whether screen time and digital device use during infant feeding (DDU) were associated with postpartum depressive symptoms. Methods: We analysed 70 144 women in the Japan Environment and Children’s Study (JECS), a prospective birth cohort in Japan. Exposures were daily digital device use time (screen time) and DDU at one month postpartum. Screen time was modelled using restricted cubic splines, while DDU was included as a binary indicator; associations with Edinburgh Postnatal Depression Scale (EPDS) positivity (EPDS ≥9) were estimated using multivariable logistic regression adjusted for covariates. We examined EPDS positivity at one month postpartum and incident EPDS positivity at six months postpartum among women without EPDS positivity at one month. Findings: At one month, longer screen time and DDU were associated with EPDS positivity; the adjusted odds ratio (OR) for DDU was 1·20 (95% confidence interval (CI) 1·11–1·30). Among women without EPDS positivity at one month, both exposures were positively associated with EPDS positivity at six months; the adjusted OR for DDU was 1·36 (95% CI 1·21–1·52). No evidence of interaction was observed between DDU and screen time. Interpretation: Longer screen time and DDU were independently associated with postpartum EPDS positivity. These behaviours might help identify mothers who could benefit from closer assessment and early support.
- 23 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessScreen Time And Digital Device Use During Infant Feeding In Relation To Postpartum Depressive Symptoms: A Nationwide Cohort Analysis From The Japan Environment And Children’s Study
Background: Postpartum depression is common after delivery. With widespread smartphone use, concerns have arisen about its influence on maternal mental health. We examined whether screen time and digital device use during infant feeding (DDU) were associated with postpartum depressive symptoms. Methods: We analysed 70 144 women in the Japan Environment and Children’s Study (JECS), a prospective birth cohort in Japan. Exposures were daily digital device use time (screen time) and DDU at one month postpartum. Screen time was modelled using restricted cubic splines, while DDU was included as a binary indicator; associations with Edinburgh Postnatal Depression Scale (EPDS) positivity (EPDS ≥9) were estimated using multivariable logistic regression adjusted for covariates. We examined EPDS positivity at one month postpartum and incident EPDS positivity at six months postpartum among women without EPDS positivity at one month. Findings: At one month, longer screen time and DDU were associated with EPDS positivity; the adjusted odds ratio (OR) for DDU was 1·20 (95% confidence interval (CI) 1·11–1·30). Among women without EPDS positivity at one month, both exposures were positively associated with EPDS positivity at six months; the adjusted OR for DDU was 1·36 (95% CI 1·21–1·52). No evidence of interaction was observed between DDU and screen time. Interpretation: Longer screen time and DDU were independently associated with postpartum EPDS positivity. These behaviours might help identify mothers who could benefit from closer assessment and early support.
- Open Access
- 25 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7609
Molecular and Genomic Mechanisms Linking Diabetes Mellitus and Periodontitis: From Pathogenesis to Translational Opportunities
Diabetes mellitus and periodontitis are bidirectionally associated chronic disorders linked through metabolic dysregulation, host inflammation, microbial dysbiosis, and impaired tissue remodeling. This review summarizes clinical, molecular, cellular, genomic, epigenomic, transcriptomic, and microbial evidence concerning the mechanisms underlying this relationship and their potential translational relevance. Chronic hyperglycemia is associated with advanced glycation end product signaling through the receptor for advanced glycation end products, mitogen-activated protein kinase/nuclear factor-κB activation, reactive oxygen species production, oxidative stress, and NLR family pyrin domain-containing 3 inflammasome activation, which may contribute to enhanced cytokine responses and periodontal tissue injury. Diabetes is also associated with altered neutrophil and macrophage function, increased T helper 17/interleukin-17 signaling, and an elevated receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio, thereby favoring osteoclastogenesis and alveolar bone loss. Conversely, periodontal inflammation and microbial products may contribute to systemic low-grade inflammation, insulin resistance, and metabolic dysregulation. Multi-omics studies have identified shared susceptibility loci, regulatory networks, and disease-associated cell states, although their causal and clinical significance remains incompletely defined. These findings suggest potential roles for integrated medical–dental care, glycemic screening in dental settings, periodontal inflammation control, host-modulatory therapies, and regenerative biomaterials. Further longitudinal and experimental studies are needed to determine their clinical applicability.
- 25 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7609
Open AccessMolecular and Genomic Mechanisms Linking Diabetes Mellitus and Periodontitis: From Pathogenesis to Translational Opportunities
Diabetes mellitus and periodontitis are bidirectionally associated chronic disorders linked through metabolic dysregulation, host inflammation, microbial dysbiosis, and impaired tissue remodeling. This review summarizes clinical, molecular, cellular, genomic, epigenomic, transcriptomic, and microbial evidence concerning the mechanisms underlying this relationship and their potential translational relevance. Chronic hyperglycemia is associated with advanced glycation end product signaling through the receptor for advanced glycation end products, mitogen-activated protein kinase/nuclear factor-κB activation, reactive oxygen species production, oxidative stress, and NLR family pyrin domain-containing 3 inflammasome activation, which may contribute to enhanced cytokine responses and periodontal tissue injury. Diabetes is also associated with altered neutrophil and macrophage function, increased T helper 17/interleukin-17 signaling, and an elevated receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio, thereby favoring osteoclastogenesis and alveolar bone loss. Conversely, periodontal inflammation and microbial products may contribute to systemic low-grade inflammation, insulin resistance, and metabolic dysregulation. Multi-omics studies have identified shared susceptibility loci, regulatory networks, and disease-associated cell states, although their causal and clinical significance remains incompletely defined. These findings suggest potential roles for integrated medical–dental care, glycemic screening in dental settings, periodontal inflammation control, host-modulatory therapies, and regenerative biomaterials. Further longitudinal and experimental studies are needed to determine their clinical applicability.
- Open Access
- 4 August 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (11) , 1876-1887
Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus
Objectives: We aimed to identify microribonucleic acids (miRNAs) that could serve as biomarkers for slowly progressive type 1 diabetes mellitus (SPIDDM). Materials and Methods: We conducted a retrospective study of adult patients with SPIDDM who fulfilled the criteria for SPIDDM (definite) ( n = 60), type 2 diabetes mellitus (T2DM) ( n = 59), and healthy controls ( n = 50) to analyze the serum expression levels of 40 miRNAs reported to be altered in latent autoimmune diabetes in adults and type 1 diabetes using quantitative real‐time polymerase chain reaction, specifically analyzing serum collected at the time of diagnosis as SPIDDM (probable) in the SPIDDM group. For miRNAs showing significant differences between the groups, we performed logistic regression analysis. In the SPIDDM group, we performed linear regression analysis on miRNAs correlated with the C‐peptide index (CPI) at the last outpatient visit as identified by Spearman's rank correlation. Results: The serum expression levels of miR‐143‐3p, miR‐21‐5p, miR‐223‐3p, and miR‐517b‐3p differed significantly in the SPIDDM group compared with the type 2 diabetes mellitus and control groups. Multivariate logistic regression analysis distinguishing SPIDDM from type 2 diabetes mellitus revealed miR‐21‐5p, miR‐223‐3p, and miR‐517b‐3p as independent discriminators. Correlation and multivariate linear regression analyses revealed that miR‐150‐5p was selected as an independent predictor of CPI at the last outpatient visit. Conclusion: This study identified serum miRNAs as potential biomarkers in adult patients with SPIDDM, particularly miR‐150‐5p as a candidate marker for predicting subsequent decline in insulin secretion.
- 4 August 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (11) , 1876-1887
Open AccessSerum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus
Objectives: We aimed to identify microribonucleic acids (miRNAs) that could serve as biomarkers for slowly progressive type 1 diabetes mellitus (SPIDDM). Materials and Methods: We conducted a retrospective study of adult patients with SPIDDM who fulfilled the criteria for SPIDDM (definite) ( n = 60), type 2 diabetes mellitus (T2DM) ( n = 59), and healthy controls ( n = 50) to analyze the serum expression levels of 40 miRNAs reported to be altered in latent autoimmune diabetes in adults and type 1 diabetes using quantitative real‐time polymerase chain reaction, specifically analyzing serum collected at the time of diagnosis as SPIDDM (probable) in the SPIDDM group. For miRNAs showing significant differences between the groups, we performed logistic regression analysis. In the SPIDDM group, we performed linear regression analysis on miRNAs correlated with the C‐peptide index (CPI) at the last outpatient visit as identified by Spearman's rank correlation. Results: The serum expression levels of miR‐143‐3p, miR‐21‐5p, miR‐223‐3p, and miR‐517b‐3p differed significantly in the SPIDDM group compared with the type 2 diabetes mellitus and control groups. Multivariate logistic regression analysis distinguishing SPIDDM from type 2 diabetes mellitus revealed miR‐21‐5p, miR‐223‐3p, and miR‐517b‐3p as independent discriminators. Correlation and multivariate linear regression analyses revealed that miR‐150‐5p was selected as an independent predictor of CPI at the last outpatient visit. Conclusion: This study identified serum miRNAs as potential biomarkers in adult patients with SPIDDM, particularly miR‐150‐5p as a candidate marker for predicting subsequent decline in insulin secretion.
- Open Access
- 22 June 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (6) , 47713
The Role of Physiological Androgen Receptor Signaling in Female Glucose Metabolism: Potential as a Protective Factor
The androgen receptor (AR), beyond its classical roles in male sexual function and muscle maintenance, has emerged as a pivotal regulator of metabolic health. In men, age- or hypogonadism-related androgen decline is strongly associated with an increased risk of type 2 diabetes and impaired glucose tolerance, underscoring the protective role of AR signaling in glucose homeostasis. Conversely, its physiological significance in women remains largely unexplored, as clinical and basic research has predominantly focused on pathological hyperandrogenism, such as polycystic ovary syndrome (PCOS). This review delineates the genomic and non-genomic molecular mechanisms of AR action and synthesizes evidence from male genetically modified mouse models and cellular studies to clarify its role across key metabolic tissues, including skeletal muscle, liver, pancreatic β-cells, adipose tissue, and the central nervous system. Based on these insights, we hypothesize that physiological AR signaling exerts beneficial metabolic effects in women, whereas adverse metabolic outcomes are primarily associated with supraphysiological AR activation. Finally, we highlight key knowledge gaps and propose future directions to validate this hypothesis, with the goal of establishing a novel conceptual framework for understanding female metabolic homeostasis and informing sex-specific therapeutic strategies.
- 22 June 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (6) , 47713
Open AccessThe Role of Physiological Androgen Receptor Signaling in Female Glucose Metabolism: Potential as a Protective Factor
The androgen receptor (AR), beyond its classical roles in male sexual function and muscle maintenance, has emerged as a pivotal regulator of metabolic health. In men, age- or hypogonadism-related androgen decline is strongly associated with an increased risk of type 2 diabetes and impaired glucose tolerance, underscoring the protective role of AR signaling in glucose homeostasis. Conversely, its physiological significance in women remains largely unexplored, as clinical and basic research has predominantly focused on pathological hyperandrogenism, such as polycystic ovary syndrome (PCOS). This review delineates the genomic and non-genomic molecular mechanisms of AR action and synthesizes evidence from male genetically modified mouse models and cellular studies to clarify its role across key metabolic tissues, including skeletal muscle, liver, pancreatic β-cells, adipose tissue, and the central nervous system. Based on these insights, we hypothesize that physiological AR signaling exerts beneficial metabolic effects in women, whereas adverse metabolic outcomes are primarily associated with supraphysiological AR activation. Finally, we highlight key knowledge gaps and propose future directions to validate this hypothesis, with the goal of establishing a novel conceptual framework for understanding female metabolic homeostasis and informing sex-specific therapeutic strategies.
- Open Access
- 15 June 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (8) , 1335-1347
Monocyte dipeptidyl peptidase 4 activity is associated with urinary albumin excretion in type 2 diabetes
Introduction: Previous reports have suggested the involvement of pro‐inflammatory genes in monocytes and dipeptidyl peptidase 4 (DPP4) in the pathogenesis of diabetic kidney disease (DKD); however, whether DPP4 in monocytes is associated with renal parameters remains unclear. Materials and Methods: We conducted a cross‐sectional study of 64 patients with type 2 diabetes mellitus (T2DM) not taking incretin‐based medications and 50 healthy controls not taking any medication and without cardiovascular risk factors. Peripheral blood monocytes were isolated from the participants, cultured, and stimulated with vehicle or lipopolysaccharide (LPS). After cell harvesting, data regarding DPP4 and pro‐inflammatory genes in monocytes were investigated by quantitative real‐time polymerase chain reaction and DPP4 activity assay. We evaluated renal parameters based on the urinary albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). Results: DPP4 gene expression and DPP4 activity in unstimulated monocytes were elevated in patients with T2DM compared with healthy controls. In the T2DM group, DPP4 gene expression in LPS‐stimulated monocytes, but not in unstimulated monocytes, was significantly and positively correlated with UACR and the expression of LPS‐stimulated pro‐inflammatory genes, but not with eGFR. Furthermore, DPP4 activity in both unstimulated and LPS‐stimulated monocytes in the T2DM group was significantly and positively correlated with UACR and the expression of LPS‐stimulated pro‐inflammatory genes but not with eGFR. Conclusions: The findings suggested that monocyte DPP4 activity is associated with urinary albumin excretion in patients with T2DM, with or without LPS stimulation. Monocytes may serve as a cellular link between DPP4 and DKD.
- 15 June 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (8) , 1335-1347
Open AccessMonocyte dipeptidyl peptidase 4 activity is associated with urinary albumin excretion in type 2 diabetes
Introduction: Previous reports have suggested the involvement of pro‐inflammatory genes in monocytes and dipeptidyl peptidase 4 (DPP4) in the pathogenesis of diabetic kidney disease (DKD); however, whether DPP4 in monocytes is associated with renal parameters remains unclear. Materials and Methods: We conducted a cross‐sectional study of 64 patients with type 2 diabetes mellitus (T2DM) not taking incretin‐based medications and 50 healthy controls not taking any medication and without cardiovascular risk factors. Peripheral blood monocytes were isolated from the participants, cultured, and stimulated with vehicle or lipopolysaccharide (LPS). After cell harvesting, data regarding DPP4 and pro‐inflammatory genes in monocytes were investigated by quantitative real‐time polymerase chain reaction and DPP4 activity assay. We evaluated renal parameters based on the urinary albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). Results: DPP4 gene expression and DPP4 activity in unstimulated monocytes were elevated in patients with T2DM compared with healthy controls. In the T2DM group, DPP4 gene expression in LPS‐stimulated monocytes, but not in unstimulated monocytes, was significantly and positively correlated with UACR and the expression of LPS‐stimulated pro‐inflammatory genes, but not with eGFR. Furthermore, DPP4 activity in both unstimulated and LPS‐stimulated monocytes in the T2DM group was significantly and positively correlated with UACR and the expression of LPS‐stimulated pro‐inflammatory genes but not with eGFR. Conclusions: The findings suggested that monocyte DPP4 activity is associated with urinary albumin excretion in patients with T2DM, with or without LPS stimulation. Monocytes may serve as a cellular link between DPP4 and DKD.
- Open Access
Association Between FTO rs1558902 Polymorphism, Age‐Related Hypogonadism, and Central Obesity in Japanese Men
Background: Obesity and low testosterone levels are closely interconnected, with the FTO gene being the most robust genetic determinant of body mass index (BMI). However, whether this primary genetic driver of obesity directly influences the hypothalamic‐pituitary‐testicular (HPT) axis remains unclear. Materials and Methods: In this cross‐sectional study of 251 Japanese men, we performed genotyping for the FTO rs1558902 polymorphism. Anthropometric measurements (BMI and waist‐to‐hip ratio [WHR]), total testosterone (tT), free testosterone (fT), luteinizing hormone (LH), and follicle‐stimulating hormone (FSH) levels were assessed. Central obesity was defined as WHR ≥ 0.9. Results: The FTO A‐allele frequency was 35.9%. A‐allele carriers had significantly higher BMI than non‐carriers ( p < 0.05), but no significant differences were found in tT or fT levels between genotypes. tT was inversely correlated with BMI and WHR ( p < 0.01). Men with central obesity exhibited significantly lower tT and fT levels alongside elevated LH and FSH levels ( p < 0.05). Multivariate analysis confirmed that the FTO genotype was not independently associated with testosterone levels. Conclusions: Although the FTO rs1558902 polymorphism was associated with a higher BMI, it did not directly correlate with testosterone levels in Japanese men. This suggests that a genetic predisposition to obesity may not be a direct determinant of low testosterone levels. Instead, the observed elevation of gonadotropins in men with central obesity highlights the significant impact of age‐related testicular dysfunction.
Open AccessAssociation Between FTO rs1558902 Polymorphism, Age‐Related Hypogonadism, and Central Obesity in Japanese Men
Background: Obesity and low testosterone levels are closely interconnected, with the FTO gene being the most robust genetic determinant of body mass index (BMI). However, whether this primary genetic driver of obesity directly influences the hypothalamic‐pituitary‐testicular (HPT) axis remains unclear. Materials and Methods: In this cross‐sectional study of 251 Japanese men, we performed genotyping for the FTO rs1558902 polymorphism. Anthropometric measurements (BMI and waist‐to‐hip ratio [WHR]), total testosterone (tT), free testosterone (fT), luteinizing hormone (LH), and follicle‐stimulating hormone (FSH) levels were assessed. Central obesity was defined as WHR ≥ 0.9. Results: The FTO A‐allele frequency was 35.9%. A‐allele carriers had significantly higher BMI than non‐carriers ( p < 0.05), but no significant differences were found in tT or fT levels between genotypes. tT was inversely correlated with BMI and WHR ( p < 0.01). Men with central obesity exhibited significantly lower tT and fT levels alongside elevated LH and FSH levels ( p < 0.05). Multivariate analysis confirmed that the FTO genotype was not independently associated with testosterone levels. Conclusions: Although the FTO rs1558902 polymorphism was associated with a higher BMI, it did not directly correlate with testosterone levels in Japanese men. This suggests that a genetic predisposition to obesity may not be a direct determinant of low testosterone levels. Instead, the observed elevation of gonadotropins in men with central obesity highlights the significant impact of age‐related testicular dysfunction.
- Open Access
- 19 May 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (8) , 1379-1386
Cholesterol accumulation in monocytes is associated with the severity of diabetic complications and the efficacy of glycemic control interventions in patients with type 2 diabetes
Aims/Introduction: Monocyte dysfunction is central to the pathogenesis of diabetes. This study investigated the association between cholesterol accumulation in monocytes and diabetic complications as well as post‐discharge glycemic control. Materials and Methods: We conducted a retrospective two‐part study. Study 1, a cross‐sectional study, included 40 patients with type 2 diabetes mellitus to assess the associations between monocyte cholesterol levels and diabetic complication indices. Study 2, a longitudinal study, included 19 patients with type 2 diabetes mellitus hospitalized for an approximately 2‐week educational program. Changes in monocyte cholesterol levels from admission to discharge were compared between two groups: those whose hemoglobin A1c (HbA1c) increased 3 months after discharge (HbA1c elevated group; n = 10) and those whose HbA1c decreased or remained stable (HbA1c non‐elevated group; n = 9). Results: In Study 1, monocyte cholesterol levels correlated with the severity of diabetic complications, including carotid intima‐media thickness, the fibrosis‐4 index, and retinopathy stage. In Study 2, during hospitalization, no significant change in monocyte cholesterol levels was observed in all patients, while a significant decrease was demonstrated in the HbA1c non‐elevated group. Conclusions: Monocytic cholesterol accumulation is associated with the severity of diverse diabetic complications and predicts the risk of glycemic deterioration after discharge. These findings suggest that monocytic cholesterol could serve as a novel translational biomarker for ‘metabolic memory’ and therapeutic resistance in type 2 diabetes mellitus.
- 19 May 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (8) , 1379-1386
Open AccessCholesterol accumulation in monocytes is associated with the severity of diabetic complications and the efficacy of glycemic control interventions in patients with type 2 diabetes
Aims/Introduction: Monocyte dysfunction is central to the pathogenesis of diabetes. This study investigated the association between cholesterol accumulation in monocytes and diabetic complications as well as post‐discharge glycemic control. Materials and Methods: We conducted a retrospective two‐part study. Study 1, a cross‐sectional study, included 40 patients with type 2 diabetes mellitus to assess the associations between monocyte cholesterol levels and diabetic complication indices. Study 2, a longitudinal study, included 19 patients with type 2 diabetes mellitus hospitalized for an approximately 2‐week educational program. Changes in monocyte cholesterol levels from admission to discharge were compared between two groups: those whose hemoglobin A1c (HbA1c) increased 3 months after discharge (HbA1c elevated group; n = 10) and those whose HbA1c decreased or remained stable (HbA1c non‐elevated group; n = 9). Results: In Study 1, monocyte cholesterol levels correlated with the severity of diabetic complications, including carotid intima‐media thickness, the fibrosis‐4 index, and retinopathy stage. In Study 2, during hospitalization, no significant change in monocyte cholesterol levels was observed in all patients, while a significant decrease was demonstrated in the HbA1c non‐elevated group. Conclusions: Monocytic cholesterol accumulation is associated with the severity of diverse diabetic complications and predicts the risk of glycemic deterioration after discharge. These findings suggest that monocytic cholesterol could serve as a novel translational biomarker for ‘metabolic memory’ and therapeutic resistance in type 2 diabetes mellitus.
- Open Access
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Double filtration plasmapheresis in antithyroid drug-refractory Graves disease with a massive goiter
We report a case of double filtration plasmapheresis (DFPP) performed in medication-resistant Graves disease (GD) with a massive goiter. A 19-year-old female was diagnosed with GD and initially demonstrated poor medication compliance. She presented with loss of consciousness from hypoxemia due to goiter-related tracheal narrowing. Despite inpatient drug therapy, the thyroid hormone levels remained high. We performed DFPP to control thyrotoxicosis before proceeding with thyroidectomy. After 4 sessions, thyroid hormone levels improved, enabling total thyroidectomy. GD with a large goiter may be refractory to medical therapy. In such cases, DFPP can improve thyroid hormone levels.
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Open AccessDouble filtration plasmapheresis in antithyroid drug-refractory Graves disease with a massive goiter
We report a case of double filtration plasmapheresis (DFPP) performed in medication-resistant Graves disease (GD) with a massive goiter. A 19-year-old female was diagnosed with GD and initially demonstrated poor medication compliance. She presented with loss of consciousness from hypoxemia due to goiter-related tracheal narrowing. Despite inpatient drug therapy, the thyroid hormone levels remained high. We performed DFPP to control thyrotoxicosis before proceeding with thyroidectomy. After 4 sessions, thyroid hormone levels improved, enabling total thyroidectomy. GD with a large goiter may be refractory to medical therapy. In such cases, DFPP can improve thyroid hormone levels.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0303
Transient pancreatic enlargement with peripancreatic inflammatory changes two days before clinical presentation and diagnosis of atezolizumab-related fulminant type 1 diabetes mellitus followed by pancreatic atrophy: a case report with review of literature
Immune checkpoint inhibitor (ICI)-related type 1 diabetes is a rare but potentially life-threatening immune-related adverse event, and imaging findings immediately before clinical presentation and diagnosis have rarely been documented. We report a 71-year-old woman with large cell neuroendocrine carcinoma who developed fulminant type 1 diabetes mellitus during carboplatin, nab-paclitaxel, and atezolizumab therapy. The day of clinical presentation and diagnosis was defined as Day 0. On Day –1, she developed nausea and appetite loss without abdominal pain. On Day 0, she presented with impaired consciousness and fever; laboratory evaluation showed plasma glucose 1,435 mg/dL, glycated hemoglobin (HbA1c) 6.9%, marked ketonemia, severe hyperosmolality, negative anti-glutamic acid decarboxylase (GAD) antibody, and near-complete insulin deficiency. The metabolic presentation was interpreted as diabetic ketoacidosis/hyperosmolar hyperglycemic state (DKA/HHS) overlap. Computed tomography (CT) performed on Day –2 showed radiologic enlargement of the pancreatic tail with increased peripancreatic fat attenuation, both of which had resolved on Day 0. Pancreatic volume increased from 46.0 mL at baseline to 82.5 mL on Day –2, decreased to 47.9 mL on Day 0, and further declined to 39.0 mL at 6-month follow-up. This hypothesis-generating case documents incidental transient pancreatic enlargement with peripancreatic inflammatory changes shortly before diagnosis, followed by pancreatic atrophy. This case suggests that incidental pancreatic enlargement during ICI therapy may serve as an early radiologic clue to immune-related diabetes, supporting prompt metabolic evaluation even in the absence of abdominal pain or pancreatic enzyme elevation.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0303
Open AccessTransient pancreatic enlargement with peripancreatic inflammatory changes two days before clinical presentation and diagnosis of atezolizumab-related fulminant type 1 diabetes mellitus followed by pancreatic atrophy: a case report with review of literature
Immune checkpoint inhibitor (ICI)-related type 1 diabetes is a rare but potentially life-threatening immune-related adverse event, and imaging findings immediately before clinical presentation and diagnosis have rarely been documented. We report a 71-year-old woman with large cell neuroendocrine carcinoma who developed fulminant type 1 diabetes mellitus during carboplatin, nab-paclitaxel, and atezolizumab therapy. The day of clinical presentation and diagnosis was defined as Day 0. On Day –1, she developed nausea and appetite loss without abdominal pain. On Day 0, she presented with impaired consciousness and fever; laboratory evaluation showed plasma glucose 1,435 mg/dL, glycated hemoglobin (HbA1c) 6.9%, marked ketonemia, severe hyperosmolality, negative anti-glutamic acid decarboxylase (GAD) antibody, and near-complete insulin deficiency. The metabolic presentation was interpreted as diabetic ketoacidosis/hyperosmolar hyperglycemic state (DKA/HHS) overlap. Computed tomography (CT) performed on Day –2 showed radiologic enlargement of the pancreatic tail with increased peripancreatic fat attenuation, both of which had resolved on Day 0. Pancreatic volume increased from 46.0 mL at baseline to 82.5 mL on Day –2, decreased to 47.9 mL on Day 0, and further declined to 39.0 mL at 6-month follow-up. This hypothesis-generating case documents incidental transient pancreatic enlargement with peripancreatic inflammatory changes shortly before diagnosis, followed by pancreatic atrophy. This case suggests that incidental pancreatic enlargement during ICI therapy may serve as an early radiologic clue to immune-related diabetes, supporting prompt metabolic evaluation even in the absence of abdominal pain or pancreatic enzyme elevation.